Mochida Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Mochida Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Mochida Pharmaceutical Co Ltd Strategy Report
- Understand Mochida Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Mochida Pharmaceutical Co Ltd (Mochida) develops, manufactures, and markets pharmaceutical and healthcare products including generics, specialty pharmaceuticals, and biosimilar products.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Mochida’s R&D focuses on developing therapeutics for cardiovascular, obesity, obstetrics, gynaecology, psychiatry and digestive organs. The company is advancing MD-0901, an oral formulation of mesalazine in Phase III clinical trials for the treatment of ulcerative colitis. It in-licensed MD-0901 from Shire, a subsidiary of Takeda. It is developing ACT-541468, an oral daridorexant in Phase ? for Co-development with Idorsia Pharmaceuticals, MND-21, an oral formulation of ethyl icosapentate in Phase III clinical trials in collaboration with Sumitomo for the treatment of hypertriglyceridemia; MD-711, an inhalant of treprostinil in Phase II/III clinical trials licensed from United Therapeutics for the treatment of pulmonary arterial hypertension; ACT-541468, an oral formulation of daridoxeant in Phase II trials in collaboration with Idorsia Pharmaceuticals for insomnia. Mochida is also advancing dMD-001, a sodium alginate medical device for articular cartilage lesion and dMD-002 for sodium alginate for Cavernous nerve injury.
Business Segments
Overview
Offers products in areas of dermatology such as sensitive skin, antimicrobial personal care, baby care and nursing products. Major products portfolio includes the Collage series, a skin series for delicate skin; Collage soap for each specific skin type; Collage D Medi Power series moisturizing products for dry skin; Collage Furfur Next shampoo and rinse which include antimycotic agent for customers with dandruff and itchy scalp; Skina Babe for baby skin care; Skina Fukifuki, Skina Clen, skin cleansing, bed bath products, and Skina Dry Shampoo for the bedridden. Markets its products to specialty pharmacies and drugstores through mail orders. It works in collaboration with dermatologists to develop new products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and supplies therapeutics in the areas of cardiology, psychiatry, obstetrics and gynaecology, dermatology, and digestive medicine. Major products includes Epadel for the treatment of arteriosclerosis obliterans and hyperlipidaemia; Dinagest for the treatment of endometriosis, adenomyosis and dysmenorrhea; Lexapro for depression and depressive symptoms; Goofice for chronic constipation; Lialda for ulcerative colitis; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Atelec, a calcium channel blocker for the treatment of hypertension; Doxil, an anticancer agent; Tramcet, an analgesic indicated for chronic pain, pain after tooth extraction; Treprost for pulmonary arterial hypertension; Movicol for chronic constipation; Heparin Sodium for Injection, an anticoagulant agent for for thrombosis; Arasena-A, antiviral drug for the treatment of herpes zoster, herpes simplex, and herpes simplex encephalitis; Florid, an antimycotic drug; Beselna indicated for condyloma acuminatum, actinic keratosis; and Miracrid for the treatment of acute pancreatitis and shock. Works in partnership with Sanofi, Bayer Healthcare, Nippon Suisan, Servier, Janssen, Lundbeck, Fuji Pharma, Gedeon Richter, Hospira, and iNova Pahramaceuticals, among others to in license products to its portfolio.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer